Vaxart Inc (AVIR):企業の財務・戦略的SWOT分析

◆英語タイトル:Vaxart Inc (AVIR) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C12809
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Vaxart Inc (AVIR) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vaxart Inc (Vaxart) formerly Aviragen Therapeutics Inc is a clinical-stage pharmaceutical company that develops oral recombinant vaccines based on its proprietary delivery platform. It is developing prophylactic vaccine candidates for a range of infectious diseases including norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company is also developing a therapeutic immune-oncology vaccine which targets cervical cancer and dysplasia caused by human papillomavirus (HPV). Vaxart’s vaccines are room temperature-stable tablets that can be stored and shipped without refrigeration. Vaxart is headquartered in San Francisco, California, the US.

Vaxart Inc Key Recent Developments

Nov 28,2018: Vaxart to Present at World Vaccine and Immunotherapy Congress West Coast 2018
Nov 09,2018: Vaxart announces third quarter 2018 financial results and provides corporate update
Oct 04,2018: New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity
Oct 04,2018: New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity
Oct 04,2018: New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Vaxart Inc – Key Facts 6
Vaxart Inc – Key Employees 7
Vaxart Inc – Key Employee Biographies 8
Vaxart Inc – Major Products and Services 9
Vaxart Inc – History 10
Vaxart Inc – Company Statement 12
Vaxart Inc – Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2 – Company Analysis 14
Company Overview 14
Vaxart Inc – Business Description 15
Vaxart Inc – Corporate Strategy 16
Vaxart Inc – SWOT Analysis 17
SWOT Analysis – Overview 17
Vaxart Inc – Strengths 17
Vaxart Inc – Weaknesses 18
Vaxart Inc – Opportunities 19
Vaxart Inc – Threats 20
Vaxart Inc – Key Competitors 21
Section 3 – Company Financial Ratios 22
Financial Ratios – Capital Market Ratios 22
Financial Ratios – Annual Ratios 23
Performance Chart 25
Financial Performance 25
Financial Ratios – Interim Ratios 26
Financial Ratios – Ratio Charts 27
Section 4 – Company’s Lifesciences Financial Deals and Alliances 28
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
Vaxart Inc, Recent Deals Summary 30
Section 5 – Company’s Recent Developments 31
Nov 28, 2018: Vaxart to Present at World Vaccine and Immunotherapy Congress West Coast 2018 31
Nov 09, 2018: Vaxart announces third quarter 2018 financial results and provides corporate update 32
Oct 04, 2018: New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity 33
Oct 04, 2018: New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity 35
Aug 09, 2018: Vaxart announces second quarter 2018 financial results and corporate update 36
May 15, 2018: Vaxart Announces First Quarter 2018 Financial Results and Corporate Update 37
Apr 19, 2018: Vaxart Appoints Brant Biehn As Senior Vice President, Commercial Operations 38
Apr 16, 2018: Vaxart to Present at Two Upcoming Medical Meetings 39
Nov 02, 2017: Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results 40
Aug 31, 2017: Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results 41
Section 6 – Appendix 42
Methodology 42
Ratio Definitions 42
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Vaxart Inc, Key Facts 6
Vaxart Inc, Key Employees 7
Vaxart Inc, Key Employee Biographies 8
Vaxart Inc, Major Products and Services 9
Vaxart Inc, History 10
Vaxart Inc, Subsidiaries 13
Vaxart Inc, Key Competitors 21
Vaxart Inc, Ratios based on current share price 22
Vaxart Inc, Annual Ratios 23
Vaxart Inc, Annual Ratios (Cont...1) 24
Vaxart Inc, Interim Ratios 26
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
Vaxart Inc, Recent Deals Summary 30
Currency Codes 42
Capital Market Ratios 42
Equity Ratios 43
Profitability Ratios 43
Cost Ratios 44
Liquidity Ratios 44
Leverage Ratios 45
Efficiency Ratios 45

List of Figures
Vaxart Inc, Performance Chart (2013 - 2017) 25
Vaxart Inc, Ratio Charts 27
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Vaxart Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29

★海外企業調査レポート[Vaxart Inc (AVIR):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NIMAB Holding AB:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' NIMAB Holding AB Mergers and Ac …
  • Bioo Therapeutics:製品開発パイプライン動向2015
    Bioo Therapeutics - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘Bioo Therapeutics - Product Pipeline Review - 2015’, provides an overview of the Bioo Therapeutics’s pharmaceutical research and development focus. This report provides comprehensive information on the current thera …
  • Infosys Limited:企業の戦略・SWOT・財務分析
    SummaryInfosys Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Finding …
  • Commerce Resources Corp. (CCE):企業概要、財務及び戦略的SWOT分析
    Summary Commerce Resources Corp. (Commerce Resources) is a mineral exploration company. The company acquires, explores, develops and evaluates mineral resource properties in British Columbia, Canada. It explores for tantalum and niobium. Commerce Resources develops tantalum and niobium deposit at th …
  • Intershop Communications AG (ISH2):企業概要、財務及び戦略的SWOT分析
    Summary Intershop Communications AG (Intershop) is an information technology company. The company develops and offers integrated e-commerce solutions to its clients. It provides services such as product information management, web content management, order management, extended B2B, search and naviga …
  • Provectus Biopharmaceuticals Inc (PVCT):製薬・医療:M&Aディール及び事業提携情報
    Summary Provectus Biopharmaceuticals Inc (Provectus) is a developer of pharmaceuticals for oncology and dermatology indications. The company provides pipeline products such as PV-10 for locally advanced cutaneous melanoma, PV-10 for metastatic liver cancer and PV-10 for neuroendocrine tumors [NET], …
  • CardioNet, Inc. (BEAT):企業概要、財務及び戦略的SWOT分析
    Summary CardioNet, Inc. (CardioNet) is a medical device company. The company supplies mobile cardiac outpatient telemetry. It carries out the development and marketing of mobile cardiac outpatient telemetry, which is used in the diagnosis and treatment of arrhythmias. CardioNet offers ambulatory, co …
  • Slavneft (SLAV):企業の財務及び戦略的SWOT分析
    Summary Slavneft (NGK Slavneft) is an oil and gas company. The company produces, sells and distributes oil products from exploration of hydrocarbon reserves and final oil products. Its products include oil and natural gas. The company has oil and gas exploration, development and production license a …
  • Msg Life AG (MSGL):企業の財務及び戦略的SWOT分析
    Summary Msg Life AG (Msg Life) is a software company that provides consulting, software, and cloud solutions for life insurance and pension scheme providers. The company offers services such as financial reporting, proposal and risk assessment, pension settlement and documentation, policy administra …
  • SynergEyes Inc:医療機器:M&Aディール及び事業提携情報
    Summary SynergEyes Inc (SynergEyes) is a medical device company that provides contact lenses. The company provides hybrid contact lenses to transform vision for patients with astigmatism, presbyopia, presbyopia, myopia, hyperopia, keratoconus, and other eye conditions. It offers ultrahealth hybrid l …
  • Scancell Holdings Plc (SCLP):企業の財務及び戦略的SWOT分析
    Summary Scancell Holdings Plc (Scancell) is a biopharmaceutical company that manufactures and distributes products for the treatment of cancer. The company’s product SCIB1 is a cancer vaccine, which is used in the treatment of melanoma. Scancell’s product stimulates immune responses to the lung canc …
  • Wolverine World Wide, Inc.:企業の戦略・SWOT・財務情報
    Wolverine World Wide, Inc. - Strategy, SWOT and Corporate Finance Report Summary Wolverine World Wide, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • National Peroxide Limited (500298):企業概要、財務及び戦略的SWOT分析
    Summary National Peroxide Limited (NPL) is a chemical company. The company manufactures and markets chemical such as hydrogen peroxide, sodium perborate, and per acetic acid. It manufactures hydrogen peroxide using auto-oxidation process through its manufacturing plant in Kalyan, Maharashtra. NPL's …
  • SolarReserve Inc.:企業のM&A・提携動向(発電分野)
    Summary SolarReserve Inc. (SolarReserve) is a developer of large-scale solar energy projects which include electricity generation by solar thermal energy and photovoltaic (PV) panels. It offers renewable and conventional energy project development services. The company’s services include engineering …
  • ADC Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報
    Summary ADC Therapeutics SA (ADCT) is a pharmaceutical company that develops a pipeline of proprietary antibody drug conjugates for the treatment of both solid and hematological cancers. The company offers combining monoclonal antibodies specific to particular types of tumor cells with a novel class …
  • Cosmo Films Limited:企業の戦略・SWOT・財務分析
    Cosmo Films Limited - Strategy, SWOT and Corporate Finance Report Summary Cosmo Films Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Globeimmune, Inc. (GBIM)(製薬・医療分野):企業M&A動向
    Summary Globeimmune, Inc. (Globeimmune) is a biopharmaceutical company. The company manufactures and distributes therapeutic products for cancer and infectious diseases. Its oncology products include GI-4000, GI-6207 and GI-6301. Globeimmune’s also offers products for infectious disease platform, su …
  • Dot Foods, Inc.:企業の戦略・SWOT・財務分析
    Dot Foods, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dot Foods, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • JFE Engineering Corporation:企業のM&A・提携動向(エネルギー分野)
    Summary JFE Engineering Corporation (JFE Engineering), a subsidiary of JFE Holdings, Inc., is an engineering company that offers engineering products and services in the field of energy, environment, steel structure and industrial machinery. The company’s product portfolio includes power generation …
  • SpringSource, Inc. (formerly Interface21):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' SpringSource, Inc. (formerly In …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆